When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
PFE - AstraZeneca and Merck's Lynparza shows treatment benefit in late-stage prostate cancer study
Pfizer Inc.
AstraZeneca (NYSE:AZN) and collaboration partner Merck (NYSE:MRK) announce positive results from a Phase 3 clinical trial, PROfound, evaluating PARP inhibitor Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) with a certain genetic profile called homologous recombination repair gene mutation (HRRm) who have progressed on prior treatment with new hormonal anticancer therapy.
More news on: AstraZeneca PLC, Merck & Co., Inc., Pfizer Inc., Healthcare stocks news,